Hypophosphatasia Clinical Trial
Official title:
A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia
This is an open-label, dose-escalating study to assess safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of ALXN1850 when given intravenous (IV) and subcutaneous (SC) to adults with HPP.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03418389 -
Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia
|
||
| Recruiting |
NCT02237625 -
Natural History Study of Patients With Hypophosphatasia (HPP)
|
||
| Completed |
NCT02291497 -
Burden of Disease in Hypophosphatasia (HPP)
|
N/A | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Active, not recruiting |
NCT04195763 -
Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
|
||
| Not yet recruiting |
NCT05596539 -
Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia (REG-HYPO)
|
||
| Completed |
NCT02751801 -
Health Burden of Hypophosphatasia
|
||
| Completed |
NCT02796885 -
Characterisation of Adult-Onset Hypophosphatasia
|
||
| Completed |
NCT05890794 -
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06079359 -
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
|
Phase 3 | |
| Recruiting |
NCT05234567 -
A Prospective Sub-Study of the Global Hypophosphatasia Registry
|
||
| Completed |
NCT02797821 -
Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
|
Phase 2 | |
| Completed |
NCT01163149 -
Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
|
Phase 2 | |
| Completed |
NCT04925804 -
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)
|
||
| Completed |
NCT02531867 -
Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan
|
Phase 4 | |
| Completed |
NCT01406977 -
Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)
|
Phase 2 | |
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Completed |
NCT01176266 -
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT00894075 -
Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)
|
Phase 2 | |
| Active, not recruiting |
NCT04222452 -
The PORTRAIT Study
|